Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells

Fig. 3

Gedatolisib significantly increased the tritium-labeled substrate-drugs accumulation in ABCB1- and ABCG2-overexpression colorectal cancer cells. a The accumulation of [3H]-paclitaxel in parental SW620 cells or resistance SW620/ADR cells after treatment with gedatolisib for 2 h. b The accumulation of [3H]-mitoxantrone in parental LS180 cells or resistance LS180/MX cells after treatment with gedatolisib for 2 h. Data were shown as mean ± SD, which is representative for three independent experiments. Asterisk presents when p value is < 0.05

Back to article page